Granite Investment Partners LLC increased its stake in shares of NeoGenomics Inc. (NASDAQ:NEO) by 6.2% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 544,119 shares of the company’s stock after buying an additional 31,635 shares during the period. Granite Investment Partners LLC owned 0.70% of NeoGenomics worth $4,473,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Falcon Point Capital LLC boosted its stake in shares of NeoGenomics by 12.5% in the second quarter. Falcon Point Capital LLC now owns 209,538 shares of the company’s stock worth $1,685,000 after buying an additional 23,216 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in shares of NeoGenomics by 14,127.6% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 142,276 shares of the company’s stock worth $959,000 after buying an additional 141,276 shares during the last quarter. Fox Run Management L.L.C. acquired a new stake in shares of NeoGenomics during the second quarter worth $171,000. Emerald Advisers Inc. PA acquired a new stake in shares of NeoGenomics during the second quarter worth $2,413,000. Finally, ClariVest Asset Management LLC acquired a new stake in shares of NeoGenomics during the second quarter worth $644,000. Institutional investors and hedge funds own 77.88% of the company’s stock.
NeoGenomics Inc. (NASDAQ:NEO) traded up 0.96% during midday trading on Friday, reaching $9.50. 269,116 shares of the company’s stock were exchanged. NeoGenomics Inc. has a 1-year low of $5.49 and a 1-year high of $9.60. The stock’s market cap is $745.86 million. The firm’s 50-day moving average is $8.16 and its 200 day moving average is $8.35.
NeoGenomics (NASDAQ:NEO) last announced its earnings results on Wednesday, October 26th. The company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.03 by $0.01. NeoGenomics had a negative net margin of 3.10% and a positive return on equity of 3.56%. The company earned $60.76 million during the quarter, compared to the consensus estimate of $61 million. During the same period in the previous year, the firm posted $0.01 earnings per share. The company’s revenue was up 141.8% on a year-over-year basis. Equities analysts anticipate that NeoGenomics Inc. will post $0.14 earnings per share for the current fiscal year.
A number of analysts recently weighed in on the stock. Axiom Securities restated a “sell” rating on shares of NeoGenomics in a report on Wednesday, November 16th. Zacks Investment Research cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. BTIG Research upgraded shares of NeoGenomics from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Thursday, October 27th. First Analysis initiated coverage on shares of NeoGenomics in a research report on Monday, October 3rd. They issued an “overweight” rating and a $11.00 price target for the company. Finally, Raymond James Financial Inc. initiated coverage on shares of NeoGenomics in a research report on Thursday, September 8th. They issued an “outperform” rating and a $10.00 price target for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have issued a buy rating to the company’s stock. NeoGenomics currently has a consensus rating of “Buy” and an average price target of $10.43.
In other news, insider Maher Albitar sold 105,300 shares of NeoGenomics stock in a transaction that occurred on Tuesday, September 20th. The shares were sold at an average price of $8.20, for a total transaction of $863,460.00. Following the completion of the sale, the insider now owns 105,300 shares in the company, valued at approximately $863,460. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 12.20% of the stock is currently owned by company insiders.
NeoGenomics Company Profile
Want to see what other hedge funds are holding NEO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeoGenomics Inc. (NASDAQ:NEO).
Receive News & Ratings for NeoGenomics Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.